- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT07583563
An Observational Study of Octreotide Subcutaneous Depot in Patients With Acromegaly
A Multi-Center, Multinational, Observational Study of Octreotide Subcutaneous Depot for the Treatment of Patients With Acromegaly
The purpose of this study is to collect long-term (up to two years) safety and effectiveness of octreotide subcutaneous depot in patients with acromegaly in the real-world setting.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Stimato)
Contatti e Sedi
Contatto studio
- Nome: Camurus AB
- Numero di telefono: +46 46 286 57 30
- Email: medicalinfo@camurus.com
Luoghi di studio
-
-
-
Aachen, Germania, 52074
- Reclutamento
- Universitaetsklinikum Aachen
-
Leipzig, Germania, 04103
- Reclutamento
- Universitaetsklinikum Leipzig
-
Magdeburg, Germania, 39110
- Reclutamento
- Fachpraxis für Innere Medizin, Endokrinologie und Diabetologie
-
München, Germania, 81667
- Non ancora reclutamento
- Medicover Neuroendokrinologie MVZ
-
Münster, Germania, 48149
- Non ancora reclutamento
- Universitätsklinikum Münster
-
Würzburg, Germania, 97080
- Reclutamento
- Universitätsklinikum Würzburg
-
-
-
-
-
Leeds, Regno Unito, LS9 7TF
- Non ancora reclutamento
- St James's University Hospital - Leeds Teaching Hospitals NHS Trust
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Metodo di campionamento
Popolazione di studio
The study will enroll patients with acromegaly who are considered for treatment with octreotide subcutaneous depot and patients with acromegaly who have already initiated octreotide subcutaneous depot treatment. The study will be conducted in Germany, the UK, and the US.
Descrizione
Inclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for acromegaly
Exclusion Criteria:
- Have started or will be starting treatment with octreotide SC depot for other conditions not related to acromegaly
- Currently taking part in an interventional clinical trial or is still within a 30-day washout period from the end of taking part in an interventional clinical trial.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Modelli osservazionali: COHORT
- Prospettive temporali: PROSPECTIVE
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Lasso di tempo |
|---|---|
|
Incidence of octreotide SC depot-related AEs and SAEs during 2 years of treatment. Focus is on related AESIs and Other Safety Information.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Change in absolute IGF-1 levels and relative IGF-1 (IGF-1/ULN) over time.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with IGF-1 ≤1×ULN over time.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in GH levels over time.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Change in proportion of participants with GH levels <1.0 μg/L over time.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Incidence of octreotide SC depot non-related AEs and incidence of laboratory abnormalities using the CTCAE grading scale.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
From enrollment to the end of treatment at 2 years
|
|
|
Changes in symptoms of acromegaly over time, as measured by the Acromegaly Index of Severity (AIS) scale.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
The clinician-reported AIS Overall Score ranges from 0 to 18, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Acromegaly Quality of Life Questionnaire (AcroQoL).
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
The AcroQoL domain scores range from 0 to 100, where a higher score indicates better quality of life. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Treatment Satisfaction Questionnaire for Medication (TSQM).
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
The TSQM domain scores range from 0 to 100, where a higher score indicates greater treatment satisfaction. |
From enrollment to the end of treatment at 2 years
|
|
Changes in QoL over time, as measured by the Assessment of Acromegaly Symptoms (AAS) questionnaire.
Lasso di tempo: From enrollment to the end of treatment at 2 years
|
The patient-reported AAS total score ranges from 0 to 48, where a higher score indicates more severe symptoms. |
From enrollment to the end of treatment at 2 years
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- HS-24-799
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .